Chun‐Ming Tsai - Concepedia

Author

Chun‐Ming Tsai

Also Known As

C M Tsai, C. Tsai, C.-M Tsai, C.-M. Tsai, C.M. Tsai, Chun-Ming Tsai, Chung-Liang Tsai, Chun‐Ming Tsai, Han-Shui Hsu, Po-Hung Lin

149

Publications

11.7K

Citations

H-Index

Concepts

All Affiliations

Taipei Veterans General Hospital National Yang Ming Chiao Tung University National Taiwan University Hospital Samsung Medical Center Sungkyunkwan University

About

Chun‐Ming Tsai is an author at Taipei Veterans General Hospital specializing in medicine, lung cancer, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	25	45	4K
2	Health Sciences	8	8	1.3K
3	Public Health	1	1	137
4	Social Sciences	1	1	27
5	Allergy	1	1	103

Chun‐Ming Tsai

Publications

11K

Citations

H-Index

Page 1

	Year	Citations
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations Lecia V. Sequist, James Chih‐Hsin Yang, Nobuyuki Yamamoto, Journal of Clinical Oncology	2013	3.2K
A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER) Yuankai Shi, Joseph S. K. Au, Sumitra Thongprasert, Journal of Thoracic Oncology	2014	1.5K
First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study Jean‐Charles Soria, Daniel S.W. Tan, Rita Chiari, The Lancet MedicineBronchial NeoplasmAdvanced AlkFirst-line CeritinibCancer Treatment	2017	1.1K
Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study Glenwood Goss, Chun‐Ming Tsai, Frances A. Shepherd, The Lancet Oncology Non-small-cell Lung CancerMedicinePathologyBronchial NeoplasmMolecular Oncology	2016	632
Mutation in the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor Is a Predictive and Prognostic Factor for Gefitinib Treatment in Patients with Non–Small Cell Lung Cancer Teh‐Ying Chou, Chao‐Hua Chiu, Ling‐Hui Li, Clinical Cancer Research	2005	321
Phase III Trial of Vandetanib Compared With Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer Ronald B. Natale, Sumitra Thongprasert, F. Anthony Greco, Journal of Clinical Oncology	2011	296
Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study Lucio Crinò, Éric Dansin, Pilar Garrido, The Lancet Oncology MedicinePhase 4First-line Bevacizumab-based TherapyImmune Checkpoint InhibitorCancer Treatment	2010	268
CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials Glenwood Goss, Chun‐Ming Tsai, Frances A. Shepherd, Annals of Oncology	2017	247
EGFR Mutation Testing Practices within the Asia Pacific Region: Results of a Multicenter Diagnostic Survey Yasushi Yatabe, Keith M. Kerr, Ahmad Rusdan Handoyo Utomo, Journal of Thoracic Oncology	2014	182
Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non–Small Cell Lung Cancer Yi‐Long Wu, Shun Lü, You Lü, Journal of Thoracic Oncology	2018	181

Page 1